The pharmaceutical portfolio of BioGenomics focuses on anti-diabetes and
anti-cancer segments since these two segments have a high impact on the
quality of life.
The anti-diabetes range of products is the most comprehensive one at BioGenomics. Human Insulin, Insulin Aspart (Rapid and Mix), Insulin Glargine,
Insulin Lispro have already completed development and are undergoing clinical trials. GLP-1 inhibitors and other advanced analogs are in development stages.
The anti-cancer pipeline of BioGenomics consists of Filgrastim and its PEGylated forms and various monoclonal antibodies. Filgrastim is currently in clinical trials and various monoclonal antibodies are in development stages.
There is an ongoing demand for these products due to emerging newer drug
delivery systems and ever expanding indications.
Bioreactor, Location: R&D centre, Thane
Comprehensive and unique products under development for Diabetes and Cancer
Partner with Us
Fill the form to know more about partnering with us.
BioGenomics is a Science driven enterprise. Led by eminent scientists, business professionals and a focussed team of molecular biologists, microbiologists and protein engineers.